Pharma Friday Roundup: This week's stories

Each Friday, we're going to share with you some of the big news from the past week in Pharma.  If you see a story that isn't covered and you'd like to see it on the Future of Biopharma blog, feel free to email jpereira@iirusa.com and share your story!



This week's big news:
Genetic Engineering and Biotech News: Repligen Buys Novozymes Biopharma Sweden for $22.7M
AFP: Pharma giants open up drug patents in new collaboration
Physorg.com: How biological capsules respond under stress
The Pharma Letter: EuropaBio sets out views on biosimilars, saying they should not be treated like generics

Share this article with your social network, just click below to share now!

Share |

Europe's Top 5 Biotech Hotspots

Fierce Biotech has compiled their list of the top 5 biotech hotspots in Europe.

They are as follows,

• United Kingdom

• Norway

• Sweden

• Germany

• Czech Republic

From Fierce Biotech:

This year, for the first time, FierceBiotech looked into the development scene solely in Europe to see which countries have hatched the best programs to support drug discovery and innovation. That doesn't mean simply listing the largest clusters. Switzerland has had one of the best track records in Europe for developing a homegrown drug development industry, but it's done it all with private capital and virtually no public support. Eastern European countries which have been late to the biotech party have the furthest to go to catch up. But in places like the Czech Republic and Hungary they're pushing ahead quickly, anxious to leapfrog into the global mainstream. All of these project initiatives bear close observation in the U.S., where public support for biotech has been a prominent feature in a slate of key states.

For more information about the countries chosen by Fierce Biotech, please visit the article.

Share this article with your social network, just click below to share now!

Share |

Grim Outlook For UK Biotech Industry

According to PharmExec.com, the UK biotech industry could see a massive change for the worse if there isn't a turn around in profits. The article states, that one-third of publicly owned UK biotechs have less than six months’ money left in the bank, and just 0.2 percent of the London Stock Exchange is now made up of biotech companies. This could have disasterious rippling effects on the global biotech industry. After reading the full article here, what are your thoughts on the UK biotech industry?

Share this article with your social network, just click below to share now!

Share |